Navigation Links
Oncothyreon announces webcast of second quarter 2009 financial results conference call
Date:8/6/2009

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its second quarter and year end 2009 financial results on Wednesday, August 12, 2009 after the close of the U.S. and Canadian markets. Following the release, Oncothyreon's management expects to discuss these financial results and give a general business update in a conference call at 4:30 p.m. EST.

The discussion is planned for a live webcast and can be accessed at www.oncothyreon.com under the "News Events" section. It is expected that the archive of the webcast will be available approximately one hour after completion of the discussion and will be posted on the Oncothyreon website for 30 days.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
2. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
3. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
4. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
5. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
6. Oncothyreon announces closing of $11.1 million registered direct financing
7. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
8. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
9. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Oncothyreon reports first quarter 2009 financial results
11. Oncothyreon regains compliance with NASDAQ listing requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... Society for Reproductive Medicine (ASRM), a leading professional organization committed ... his new role as treasurer, Dr. Hill also fills a ... in furthering the mission of ASRM. , Dr. Hill ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... Xybion Medical ... its Research and Development facility in Fair Lawn, New Jersey. , ... Cedar Knolls, NJ (PRWEB) August 3, 2009 -- Xybion ... of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK ...
... , , , ... Inc. (Nasdaq: GHDX ) today reported financial results and business progress ... revenue increased to $36.6 million in the second quarter of 2009 compared with ... Onco type DX(R) breast cancer test was $35.2 million in the second ...
... 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd.,(ChemPartner) a wholly ... moved its drug discovery collaboration with ELARA,Pharmaceuticals to a ... the areas of DMPK, pharmacology and toxicology for ELARA,s ... from both sides will,work closely together to design and ...
Cached Biology Technology:SK Life Sciences has Licensed Pristima 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 3Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 4Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 5Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 6Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 7Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 8Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 9Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 2
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... LAFAYETTE, Ind. - Proper and timely burning of some Eastern ... a wide range of species, a Purdue University report shows. ... nutrient from deep in the soil and depositing it on ... an important source of nutrition for a variety of species ...
... been a hot savanna region for at least the past ... hominids evolved in this areasays a team of researchers led ... findings may shed light on the evolutionary pressures that led ... develop a more slender physique, and sweat more copiously than ...
... , New Rochelle, NY, June 8, 2010The growing use ... may help individuals with diabetes optimize blood glucose control ... with diabetes, as described in a Special Supplement to ... published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The issue ...
Cached Biology News:Fire may be key to reviving dogwood trees in Eastern forests 2East-African human ancestors lived in hot environments, says Caltech-led team 2East-African human ancestors lived in hot environments, says Caltech-led team 3Importance of insulin delivery devices for diabetes management 2
Request Info...
... Hematopoietic stem cells (HSC) are well-characterized tissue-specific ... and are responsible for the life-long maintenance ... cells that reside in adult bone marrow ... can also be found in cord blood, ...
... polyclonal to Atrophin 1 ( Abpromise ... Antigen: Synthetic peptide conjugated to KLH ... C-terminus of Human Atrophin 1.(Note: the amino ... ab32861 .) Entrez GeneID: ...
NNT-1/BSF-3 (N-14)...
Biology Products: